---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-23-000018"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T04:50:32.668453+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Travere's sparsentan misses primary eGFR endpoint in Phase 3 FSGS study; proteinuria trends favorable

## Summary
- eGFR total slope difference 0.3 mL/min/1.73m2/yr favoring sparsentan (p=0.7491), not statistically significant.
- eGFR chronic slope difference 0.9 mL/min/1.73m2/yr (p=0.4203), also not significant.
- Proteinuria reduced 50% with sparsentan vs 32% with irbesartan at week 108; FPRE 38% vs 23%.
- Company plans to engage FDA and EMA to explore potential path for regulatory submission.
- Sparsentan well-tolerated with safety profile comparable to irbesartan through 108 weeks.

## SEC filing metadata
- accession: 0001438533-23-000018
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000018/0001438533-23-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000018/tvtx-20230501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-23-000018
- JSON: https://secwatch.observer/filing/0001438533-23-000018.json
- Plain text: https://secwatch.observer/filing/0001438533-23-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.